

1. A method for the treatment of diseases, disorders, conditions or symptoms mediated by cell adhesion in a mammal which comprises administering to said mammal an effective amount of a compound Formula I:



15

20 wherein alkyl, alkenyl, and alkynyl are optionally substituted with one to four substituents independently selected from R^a; and Cy is optionally substituted with one to four substituents independently selected from R^b;

- 96 -

- 7) heteroaryl,
- 8) heteroaryl-C₁₋₁₀alkyl,

wherein alkyl, alkenyl, and alkynyl are optionally substituted with one to four substituents independently selected from R^a; and aryl and

- 5 heteroaryl optionally substituted with one to four substituents independently selected from R^b;

- R³ is
- 1) hydrogen,
 - 2) C₁₋₁₀ alkyl,
 - 10 3) Cy, or
 - 4) Cy-C₁₋₁₀ alkyl,

wherein alkyl is optionally substituted with one to four substituents independently selected from R^a; and Cy is optionally substituted with one to four substituents independently selected from R^b;

- 15 R⁴ is
- 1) hydrogen,
 - 2) C₁₋₁₀alkyl,
 - 3) C₂₋₁₀alkenyl,
 - 4) C₂₋₁₀alkynyl,
 - 20 5) Cy,
 - 6) Cy-C₁₋₁₀alkyl,
 - 7) Cy-C₂₋₁₀alkenyl,
 - 8) Cy-C₂₋₁₀alkynyl,

wherein alkyl, alkenyl and alkynyl are optionally substituted with one to four substituents selected from phenyl and R^x, and Cy is optionally substituted with one to four substituents independently selected from R^y;

or

- 25 R³, R⁴ and the atoms to which they are attached together form a mono- or bicyclic ring containing 0-2 additional heteroatoms selected from N, O and S;
- 30

- R⁵ is
- 1) hydrogen,
 - 2) C₁₋₁₀alkyl,

- 5

10

15

20

- 25

wherein Cy is optionally substituted with one to four substituents independently selected from R^C;

- 98 -

- wherein alkyl, alkenyl, alkynyl, aryl, heteroaryl are optionally substituted with a group independently selected from R^c;

5

R^c is

- 1) halogen,
- 2) NO₂,
- 3) C(O)OR^f,
- 4) C₁₋₄alkyl,
- 5) C₁₋₄alkoxy,
- 6) aryl,
- 7) aryl C₁₋₄alkyl,
- 8) aryloxy,
- 9) heteroaryl,
- 10) NR^fR^g,
- 11) NR^fC(O)R^g,
- 12) NR^fC(O)NR^fR^g, or
- 13) CN;

10

15

20

R^d and R^e are independently selected from hydrogen, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, Cy and Cy C₁₋₁₀alkyl, wherein alkyl, alkenyl, alkynyl and Cy is optionally substituted with one to four substituents independently selected from R^c ; or

25 ~~R^d and R^e together with the atoms to which they are attached form a heterocyclic ring of 5 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and nitrogen;~~

R^f and R^g are independently selected from hydrogen, C₁-10alkyl, Cy and Cy-C₁-10alkyl wherein Cy is optionally substituted with C₁-10alkyl; or

30 R^f and R^g together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

5

- 1) hydrogen,
- 2) C₁₋₁₀alkyl,
- 3) C₂₋₁₀alkenyl,
- 4) C₂₋₁₀alkynyl,
- 5) cyano,
- 6) aryl,
- 7) aryl C₁₋₁₀alkyl,
- 8) heteroaryl,
- 9) heteroaryl C₁₋₁₀alkyl, or
- 10) -SO₂Rⁱ;

10

wherein alkyl, alkenyl, and alkynyl are optionally substituted with one to four substituents independently selected from R^a; and aryl and heteroaryl are each optionally substituted with one to four substituents independently selected from R^b;

15

Ri

- 1) C₁₋₁₀alkyl,
- 2) C₂₋₁₀alkenyl,
- 3) C₂₋₁₀alkynyl, or
- 4) aryl;

20

wherein alkyl, alkenyl, alkynyl and aryl are each optionally substituted with one to four substituents independently selected from R^C;

R^X is 1)

- 1) -OR^d,
- 2) -NO₂,
- 3) halogen
- 4) -S(O)_mR^d,
- 5) -SR^d,
- 6) -S(O)₂OR^d,
- 7) -S(O)_mNR^dRe,
- 8) -NR^dRe,
- 9) -O(CR^fR^g)_nNR^dRe,
- 10) -C(O)R^d,
- 11) -CO₂R^d,

25

30

- 5
- 12) $-\text{CO}_2(\text{CR}^{\text{f}}\text{R}^{\text{g}})_n\text{CONR}^{\text{d}}\text{Re},$
 13) $-\text{OC}(\text{O})\text{R}^{\text{d}},$
 14) $-\text{CN},$
 15) $-\text{C}(\text{O})\text{NR}^{\text{d}}\text{Re},$
 16) $-\text{NR}^{\text{d}}\text{C}(\text{O})\text{Re},$
 17) $-\text{OC}(\text{O})\text{NR}^{\text{d}}\text{Re},$
 18) $-\text{NR}^{\text{d}}\text{C}(\text{O})\text{OR}^{\text{e}},$
 19) $-\text{NR}^{\text{d}}\text{C}(\text{O})\text{NR}^{\text{d}}\text{Re},$
 20) $-\text{CR}^{\text{d}}(\text{N}-\text{OR}^{\text{e}}),$
 10 21) $-\text{CF}_3,$
 22) $\text{oxo},$
 23) $\text{NR}^{\text{d}}\text{C}(\text{O})\text{NR}^{\text{d}}\text{SO}_2\text{R}^{\text{i}},$
 24) $\text{NR}^{\text{d}}\text{S}(\text{O})_m\text{Re},$
 25) $-\text{OS}(\text{O})_2\text{OR}^{\text{d}}, \text{ or}$
 15 26) $-\text{OP}(\text{O})(\text{OR}^{\text{d}})_2;$

- RY is
- 20
- 1) a group selected from $\text{R}^{\text{x}},$
 2) C_{1-10} alkyl,
 3) C_{2-10} alkenyl,
 4) C_{2-10} alkynyl,
 5) aryl C_{1-10} alkyl,
 6) heteroaryl C_{1-10} alkyl,
 7) cycloalkyl,
 8) heterocyclyl;

25 wherein alkyl, alkenyl, alkynyl and aryl are each optionally substituted with one to four substituents independently selected from $\text{R}^{\text{x}};$

Cy is cycloalkyl, heterocyclyl, aryl, or heteroaryl;

30 m is an integer from 1 to 2;

n is an integer from 1 to 10;

- X is
- 1) $-C(O)OR^d$,
 - 2) $-P(O)(OR^d)(OR^e)$
 - 3) $-P(O)(R^d)(OR^e)$
 - 4) $-S(O)_mOR^d$,
 - 5) $-C(O)NR^dR^h$, or
 - 6) -5-tetrazolyl;

- Y is
- 1) $-C(O)-$,
 - 2) $-O-C(O)-$,
 - 3) $-NR^e-C(O)-$,
 - 4) $-S(O)_2-$,
 - 5) $-P(O)(OR^4)$ or
 - 6) $C(O)C(O)$;

Z and A are independently selected from -C- and -C-C-;

B is selected from the group consisting of

- 1) a bond,
- 2) -C-
- 3) -C-C-,
- 3) -C=C-,
- 4) a heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur; and
- 5) $-S(O)_m-$.

2. A method of Claim 1 wherein in compounds of

Formula I,

Y is $S(O)_2$;

R¹ is

- (1) C₁-10alkyl,
- (2) Cy, or
- (3) Cy-C₁-10 alkyl;

5 3. A method of Claim 1 wherein said cell adhesion is mediated by VLA-4.

4. A method of Claim 1 wherein said disease is selected from asthma, allergic rhinitis, multiple sclerosis, atherosclerosis, inflammatory bowel disease and inflammation.

15 or a pharmaceutically acceptable salt thereof, wherein
R1, R2, R3, R4, R5, R6, R7, X, B, and Z are as defined in Claim 1 with the
proviso that R6/R7 is not oxo when attached to the carbon between N and
20 B, and with the further proviso that when B and Z are each C, R2, R3,
R6, and R7 are each H, then R1 is other than phenyl, 4-methylphenyl
and 5-(NR^dRe)naphthyl.

25 a 6. A compound of Claim ~~5~~²¹ wherein Z is C.

7. A compound of Claim ²¹~~5~~ wherein B is C, C=C, C-C or

a

8. A compound of Claim ²¹~~5~~ wherein X is C(O)OR_d.

a

9. A compound of Claim 5 wherein R¹ is C₁₋₁₀alkyl, Cy or Cy-C₁₋₁₀alkyl wherein alkyl is optionally substituted with one to two substituents independently selected from R_a, and Cy is optionally substituted with one to four substituents independently selected from R_b.

a

10. A compound of Claim 5 wherein R¹ is aryl optionally substituted with one to four substituents selected from R^b.

10
a


11. A compound of ~~Claim 5~~²¹ wherein R⁵ is H and R⁴ is C₁₋₁₀ alkyl or Cy-C₁₋₁₀alkyl, wherein alkyl is optionally substituted with one to four substituents selected from phenyl and R^x, and Cy is optionally substituted with one to four substituents independently selected from R^y; or R⁴, R⁵ and the carbon to which they are attached together form a 3-7 membered mono- or bicyclic carbon only ring.

20

12. A compound of Claim 11 wherein R⁴ is phenyl-C₁₋₃ alkyl, wherein phenyl is optionally substituted with one or two groups selected from R_Y.

a


13. A compound of Claim ^{2/}~~5~~ having the formula Ib:

**Ib**

wherein R² is H or C₁₋₆ alkyl, and R¹, R², R³, R⁴ and R⁵ and X are as defined in Claim 5.

14. A compound of Claim 13 wherein X is CO₂H; R¹ is aryl optionally substituted with one to four substituents selected from R^b; R² is H; R³ H or C₁₋₃ alkyl; R⁴ is phenyl-C₁₋₃alkyl, wherein phenyl is optionally substituted with one or two groups selected from R^y; and R⁵ is H.

15. A compound of Claim 5 having the formula Ic:



Ic

wherein R² is H or C₁₋₃ alkyl; R⁶ is H, C₁₋₆ alkyl, aryl, OR^d, SR^d, NR^dRe, or NR^dC(O)Re; B is S, C=C, C or C-C; R³ is H or C₁₋₆alkyl, R^b and R^y are as defined in Claim 5.

16. A compound of Claim 15 wherein B is C and R^b is halogen, C₁₋₁₀alkoxy, cyano, or trifluoromethyl.

17. A compound selected from the group consisting of:
(1) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-leucine;

- (2) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-arginine;
- (3) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-glutamic acid;
- (4) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-glycine;
- (5) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-(1-naphthyl)alanine;
- (6) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)- α -t-butylglycine;
- (7) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-3-(2-thienyl)alanine;
- (8) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-cyclohexylalanine;
- (9) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-3-(2-naphthyl)alanine;
- (10) N-(3,3-diphenylpropanoyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (11) N-(2,4-dinitrobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (12) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-3,3-diphenylalanine;
- (13) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
- (14) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-proline;
- (15) N-dansyl-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (16) N-(2-naphthalenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (17) N-(4-methoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;

- (18) N-(4-phenylbenzoyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (19) N-(3,4-dimethylbenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-cysteine;
- (20) N-(4-t-butylbenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (21) N-(2,5-dichlorobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (22) N-(2-mesitylenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (23) N-(p-toluenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (24) N-(4-chlorobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (25) N-(N'-acetylsulfanilyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (26) N-(4-fluorobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (27) N-(1-naphthalenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (28) N-(benzylsulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (29) N-(4-nitrobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (30) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-phenylalanine;
- (31) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-glutamine;
- (32) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-(4-nitrophenyl)alanine;
- (33) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-asparagine;

- 108 -

- (50) N-(3,4-dichlorobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl(L)-norleucine;
- (51) N-(2-trifluoromethylbenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (52) N-(2,3-dichlorobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (53) N-(2,4-dichlorobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (54) N-(2,5-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (55) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-serine;
- (56) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-isoleucine;
- (57) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-tryptophan;
- (58) N-(2,1,3-benzothiadiazole-4-sulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-tryptophan;
- (59) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-3-(3-pyridyl)alanine;
- (60) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-3-(2-naphthyl)alanine, ethyl ester;
- (61) N-acetyl-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (62) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(R)-carbonyl-(D)-norleucine;
- (63) N-propionyl-(L)-prolyl-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (64) N-(4-cyanobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (65) N-(benzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;

- (66) N-(3-nitrobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (67) N-(3-trifluoromethylbenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (68) N-(2-thienylsulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (69) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-N-methylleucine;
- (70) N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-citrulline;
- (71) N-(4-iodobenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl-(L)-norleucine;
- (72) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-(3-iodo)tyrosine;
- (73) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-3-(3-pyridyl)alanine;
- (74) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-phenylalanine;
- (75) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-glutamic acid;
- (76) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-arginine;
- (77) N-(N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl)-1-amino-cyclopentane-1-carboxylic acid;
- (78) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-3-(3,4-dichlorophenyl)alanine;
- (79) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-3-(2-naphthyl)alanine, ethyl ester;
- (80) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-3-(4-bromophenyl)alanine;
- (81) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-3-(4-nitrophenyl)alanine;
- (82) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-3-(4-thiazolyl)alanine;
- (83) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-3-(2-chlorophenyl)alanine;
- (84) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-3-(4-chlorophenyl)alanine;

- 111 -

- 112 -

- (125) N-(3-chlorobenzenesulfonyl)-(L)-4(R)-hydroxypropyl-(L)-4-fluorophenylalanine;
- (126) N-(3,5-dichlorobenzenesulfonyl)-(L)-pipecolyl-(L)-4-fluorophenylalanine;
- (127) N-(3-fluorobenzenesulfonyl)-(L)-3,4-dehydropropyl-(L)-tyrosine;
- (128) N-(4,5-dichloro-2-thiophenesulfonyl)-(L)-prolyl-(L)-tyrosine;
- (129) N-(3-fluorobenzenesulfonyl)-(L)-4(R)-hydroxypropyl-(L)-tyrosine;
- (130) N-(3-chlorobenzenesulfonyl)-(L)-4(R)-hydroxypropyl-(L)-tyrosine;
- (131) N-(3-fluorobenzenesulfonyl)-(L)-pipecolyl-(L)-4-fluorophenylalanine;
- (132) N-(3-fluorobenzenesulfonyl)-(L)-4(R)-hydroxypropyl-(L)-tyrosine, O-tert-butyl ether;
- (133) N-(3-chlorobenzenesulfonyl)-(L)-4(R)-hydroxypropyl-(L)-tyrosine, O-tert-butyl ether;
- (134) N-(4,5-dichloro-2-thiophenesulfonyl)-(L)-3,4-dehydropropyl-(L)-tyrosine
- (135) N-(3,5-dichlorobenzenesulfonyl)-(L)-3(S)-methyl-prolyl-(L)-4-fluorophenylalanine;
- (136) N-(4,5-dichloro-2-thiophenesulfonyl)-(L)-3,4-dehydropropyl-(L)-tyrosine;
- (137) N-(3-fluorobenzenesulfonyl)-(L)-3,4-dehydropropyl-(L)-tyrosine, O-tert-butyl ether;
- (138) N-(3-chlorobenzenesulfonyl)-(L)-3,4-dehydropropyl-(L)-tyrosine, O-tert-butyl ether;
- (139) N-(3-chlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-4-fluorophenylalanine;
- (140) N-(3-chlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-tyrosine;
- (141) N-(3-chlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-tyrosine, O-tert-butyl ether;
- (142) N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-tyrosine;
- (143) N-(3-fluorobenzenesulfonyl)-(L)-prolyl-(L)-3-iodotyrosine;
- (144) N-(3-chlorobenzenesulfonyl)-(L)-prolyl-(L)-3-iodotyrosine;

- 114 -

- (164) N-(5-(N-(4-chlorobenzoyl)aminomethyl)-2-thiophenesulfonyl)-(L)-prolyl-(L)-4-fluorophenylalanine;
- (165) N-(5-(3-(1-methyl-5-trifluoromethyl-pyrazoyl))-2-thiophenesulfonyl)-(L)-prolyl-(L)-4-fluorophenylalanine;
- (166) N-(3-fluorobenzenesulfonyl)-2(S)-methylprolyl-(L)-O-tert-butyl-tyrosine;
- (167) N-(3-fluorobenzenesulfonyl)-(L)-4(R)-aminoprolyl-(L)-4-fluorophenylalanine;
- (168) N-(3,5-dichlorobenzenesulfonyl)-(L)-4(R)-aminoprolyl-(L)-4-fluorophenylalanine;
- (169) N-(3-chlorobenzenesulfonyl)-(L)-4(R)-aminoprolyl-(L)-4-fluorophenylalanine;
- (170) N-(3,5-dichlorobenzenesulfonyl)-(L)-4(S)-aminoprolyl-(L)-4-fluorophenylalanine;
- (171) N-(3-chlorobenzenesulfonyl)-(L)-thiaprolyl-(L)-4-fluorophenylalanine;
- (172) N-(4-bromo-5-chloro-2-thiophenesulfonyl)-(L)-prolyl-(L)-4-fluorophenylalanine;
- (173) N-(4,5-dichloro-2-thiophenesulfonyl)-(L)-prolyl-(L)-4-fluorophenylalanine;
- (174) N-(3,5-dichlorobenzenesulfonyl)-(L)-thiaprolyl-(L)-3,5-diiodotyrosine;
- (175) N-(5-benzoylaminomethyl-2-thiophenesulfonyl)-(L)-prolyl-(L)-4-fluorophenylalanine;
- (176) N-(3-chlorobenzenesulfonyl)-(L)-prolyl-(L)-O-tert-butyl-tyrosine;
- (177) N-(5-benzenesulfonyl-2-thiophenesulfonyl)-(L)-prolyl-(L)-4-fluorophenylalanine;
- (178) N-(3-bromo-5-chloro-2-thiophenesulfonyl)-(L)-prolyl-(L)-4-fluorophenylalanine;
- (179) N-(3-chlorobenzenesulfonyl)-(L)-3,4-dehydroprolyl-(L)-tyrosine;
- (180) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-homophenylalanine;

- 116 -

- 117 -

- 118 -

- 6

- N-(3-trifluoromethylbenzenesulfonyl)-(L)-2(S)-nitro-phenylalanine;
N-(3,5-dichlorobenzenesulfonyl)-(L)-3(R)-methoxyfluorophenylalanine;
N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methoxycyanophenylalanine;
N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methoxy(aminocarbonyl)-phenylalanine;
N-(3,5-dichlorobenzenesulfonyl)-(L)-3(R)-methoxybutoxycarbonylamino-methyl-phenylalanine;
N-(3,5-dichlorobenzenesulfonyl)-(L)-3(R)-methoxy(aminomethyl)-phenylalanine;
N-(3-trifluoromethylphenylsulfonyl)-(L)-2(S)-methoxyacetaminophenylalanine;
N-(3-trifluoromethylphenylsulfonyl)-(L)-2(S)-methoxy(N'-(2-toluyloxy)ureido)phenylalanine;
N-(3-trifluoromethylphenylsulfonyl)-(L)-2(S)-methoxy(N'-(4'-fluorophenylsulfonyl)ureido)phenylalanine;
N-(3-trifluoromethylphenylsulfonyl)-(L)-2(S)-methoxy(ethoxycarbonyl)aminophenylalanine;
N-(3-trifluoromethylphenylsulfonyl)-(L)-2(S)-methoxy(N'-(2-toluyloxy)ureido)phenylacetylaminophenylalanine;
N-(3-trifluoromethylphenylsulfonyl)-(L)-2(S)-methoxyfluorophenylsulfonylaminophenylalanine;
N-(3-trifluoromethylphenylsulfonyl)-(L)-2(S)-methoxy(phenylacetyl)aminophenylalanine;
N-(3-trifluoromethylphenylsulfonyl)-(L)-2(S)-methoxyfluorobenzoylaminophenylalanine;
N-(3-trifluoromethylphenylsulfonyl)-(L)-2(S)-methoxy(isobutyloxycarbonyl)aminophenylalanine;
N-(3-trifluoromethylphenylsulfonyl)-(L)-2(S)-methoxymethylsulfonylamino-phenylalanine;
- 120 -

- 121 -

- (297) N-(3,5-dichlorobenzenesulfonyl)-2-(S)-methyl-(L)-prolyl-4-(4-cyanophenoxy)-phenylalanine;
- (298) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-tert-butyl-tyrosine;
- (299) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-methyl-tyrosine;
- (300) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-benzyl-tyrosine;
- (301) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-n-butyl-tyrosine;
- (302) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-cyanomethyl-tyrosine;
- (303) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-(2-methoxyethyl)-tyrosine;
- (304) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-(2-ethoxyethyl)-tyrosine;
- (305) N-(benzenesulfonyl)-(L)-prolyl-(L)-O-(2-methoxyethyl)-tyrosine;
- (306) N-(benzenesulfonyl)-(L)-prolyl-(L)-O-(2-ethoxyethyl)-tyrosine;
- (307) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-(1-pyrrolidinylcarbonyl)-tyrosine;
- (308) N-(benzenesulfonyl)-(L)-prolyl-(L)-O-(1-pyrrolidinylcarbonyl)-tyrosine;
- (309) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-(tert-butyl acetate)-tyrosine;
- (310) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-(4-morpholinylcarbonyl)-tyrosine;
- (311) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-(1-(2-propanonyl)-tyrosine;
- (312) N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-O-(1-pyrrolidinylcarbonyl)-tyrosine;
- (313) N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-O-(tert-butyl acetate)-tyrosine;
- (314) N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-O-(2-ethoxyethyl)-tyrosine;
- (315) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-(acetic acid)-tyrosine, methyl ester;

- (316) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-(acetic acid)-tyrosine;
- (317) N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-O-(1-(2-propanonyl)-tyrosine;
- (318) N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-O-(1-pyrrolidinylcarbonyl)-tyrosine, methyl ester;
- (319) N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-O-(4-morpholinyl-carbonyl)-tyrosine;
- (320) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-(2-pyrrolylcarbonyl)-tyrosine;
- (321) N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-O-(N-phenyl-N-methylaminocarbonyl)-tyrosine;
- (322) N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-O-(N,N-diethyl-aminocarbonyl)-tyrosine;
- (323) N-(3-chlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-O-(4-morpholinyl-carbonyl)-tyrosine;
- (324) N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-O-(N,N-diisopropyl-aminocarbonyl)-tyrosine;
- (325) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-(benzoyl)-tyrosine;
- (326) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-(cyclopentanoyl)-tyrosine;
- (327) N-(3,5-dichlorobenzenesulfonyl)-(L)-prolyl-(L)-O-(5-tetrazolyl)methyl-tyrosine;
- (328) N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-N^ε-benzyl-histidine;
- (329) N-benzenesulfonyl-(L)-prolyl-2-amino-2-norbornanecarboxylic acid;
- (330) N-benzenesulfonyl-(L)-prolyl-3(R)-methyl-phenylalanine;
- (331) N-benzenesulfonyl-(L)-prolyl-(L)-2,3-methano-phenylalanine; N-benzenesulfonyl-(L)-prolyl-(D)-2,3-methano-phenylalanine; and
- (332) N-(3,5-dichlorobenzenesulfonyl)-(L)-2(S)-methyl-prolyl-(L)-4-(5-((1H,3H)-1,3-dimethylpyrimidine-2,4-dione))-phenylalanine.

18. A method for the treatment of diseases, disorders, conditions or symptoms mediated by cell adhesion in a mammal which comprises administering to said mammal an effective amount of a compound of Claim 5.

5

19. A method for the treatment of asthma, allergic rhinitis, multiple sclerosis, atherosclerosis, inflammatory bowel disease or inflammation in a mammal which comprises administering to said mammal an effective amount of a compound of Claim 5.

10

20. A pharmaceutical composition which comprises a compound of Claim 5 and a pharmaceutically acceptable carrier thereof.

add a'

add B4

2-
D-1